Erasca, Inc. $ERAS Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC lifted its stake in Erasca, Inc. (NASDAQ:ERAS) by 64.6% during the first quarter, HoldingsChannel reports. The institutional investor owned 1,398,869 shares of the company’s stock after acquiring an additional 548,769 shares during the period. Renaissance Technologies LLC’s holdings in Erasca were worth $22,634,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ERAS. Neuberger Berman Group LLC boosted its stake in Erasca by 11.3% in the fourth quarter. Neuberger Berman Group LLC now owns 12,358 shares of the company’s stock valued at $46,000 after acquiring an additional 1,253 shares in the last quarter. Abel Hall LLC lifted its holdings in shares of Erasca by 8.1% in the 1st quarter. Abel Hall LLC now owns 16,947 shares of the company’s stock valued at $274,000 after purchasing an additional 1,265 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Erasca by 25.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,787 shares of the company’s stock valued at $51,000 after purchasing an additional 2,820 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of Erasca by 11.1% in the 4th quarter. ProShare Advisors LLC now owns 44,216 shares of the company’s stock valued at $164,000 after purchasing an additional 4,430 shares during the last quarter. Finally, KBC Group NV acquired a new stake in shares of Erasca in the 1st quarter valued at about $81,000. 67.78% of the stock is currently owned by institutional investors and hedge funds.

Erasca Trading Down 2.4%

NASDAQ:ERAS opened at $17.72 on Thursday. Erasca, Inc. has a 12-month low of $1.33 and a 12-month high of $24.28. The stock’s 50 day simple moving average is $15.90 and its 200-day simple moving average is $14.27. The firm has a market cap of $5.51 billion, a P/E ratio of -19.05 and a beta of 0.66.

Erasca (NASDAQ:ERAS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). Research analysts forecast that Erasca, Inc. will post -0.54 EPS for the current fiscal year.

Key Headlines Impacting Erasca

Here are the key news stories impacting Erasca this week:

• Neutral Sentiment: Multiple law firms reminded shareholders that August 10, 2026 is the deadline to seek appointment as lead plaintiff in a pending securities class action covering investors who purchased Erasca shares between January 14, 2025, and April 26, 2026. Berger Montague class-action reminder
• Negative Sentiment: The lawsuits allege that Erasca and certain executives misled investors about ERAS-0015’s competitive advantages, safety profile, and intellectual-property protection. These allegations could lead to legal expenses, potential damages, and additional scrutiny, although they remain unproven. Hagens Berman Erasca investor deadline
• Negative Sentiment: One notice describes a 15-month sequence involving statements at a J.P. Morgan conference, a patent-infringement letter, and a reported patient death, claiming these events contributed to investor losses of $11.59 per share. Levi and Korsinsky Erasca class-action notice
• Negative Sentiment: Another investor alert says a $258.8 million stock offering preceded a 53.9% share-price collapse, raising concerns about alleged disclosure issues and potential recovery claims. SueWallSt Erasca shareholder alert

Analyst Ratings Changes

ERAS has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Erasca in a research report on Tuesday, July 14th. Wolfe Research set a $16.00 price objective on Erasca in a report on Thursday, June 4th. Jefferies Financial Group restated a “buy” rating on shares of Erasca in a research report on Tuesday, July 14th. HSBC set a $20.00 target price on shares of Erasca in a report on Tuesday, July 14th. Finally, Mizuho decreased their price target on shares of Erasca from $28.00 to $26.00 and set an “outperform” rating for the company in a research note on Tuesday, May 12th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $21.64.

Erasca Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.